Intracameral bevacizumab for iris rubeosis.
OBJECTIVE
To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma.


METHODS
Interventional case series.


METHODS
The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography.


RESULTS
Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks.


CONCLUSIONS
Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.
Grisanti
Salvatore
S
Department of Ophthalmology I, Eberhard-Karls University of Tuebingen, Tuebingen, Germany. salvatore.grisanti@med.uni-tuebingen.de
Biester
Sabine
S
Peters
Swaantje
S
Tatar
Olcay
O
Ziemssen
Focke
F
Bartz-Schmidt
Karl Ulrich
KU
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000867:Anterior Chamber / Q000187:drug effects*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002199:Capillary Permeability / Q000187:drug effects; D003930:Diabetic Retinopathy / Q000150:complications; D005260:Female; D005451:Fluorescein Angiography; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007267:Injections; D007498:Iris / Q000098:blood supply*; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D010865:Pilot Projects; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000150:complications; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab